title: AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico.
abstract: BACKGROUND
  Non-Hodgkin lymphoma (NHL) associated with HIV became an AIDS-defining condition early in the epidemic and remains the second most common malignancy in patients with AIDS. With the advent of highly active antiretroviral therapy (HAART), the incidence and mortality of AIDS-related opportunistic infections and Kaposi's sarcoma has fallen dramatically, this trend is not observed so clearly for NHL. Our objective was to review the clinical spectrum of patients with AIDS-associated NHL and to analyze the impact of HAART on survival at an oncological tertiary center.
  
  
  METHODS
  We reviewed all medical records and histopathologic tissue of patients with HIV-associated NHL seen from January 1990 to September 2007 at the Instituto Nacional de Cancerologia in Mexico City. Survival or follow-up time was calculated from date of diagnosis to death, or to the date on which the patient was last seen.
  
  
  RESULTS
  Eighty seven HIV-positive patients were diagnosed with NHL (diffuse large B-cell lymphoma n=69; Burkitt-like n=8; pleomorphic large cell n=7; low-grade n=2, and angiocentric n=1). Twenty eight patients never received HAART, and 59 received HAART. Overall, 38 patients (43.7%) achieved complete response to NHL therapy, including only 14.3% patients in the non-HAART compared with 57.6% in the HAART group (p < or = 0.0001). Two patients (7.1%) in the non-HAART were alive compared with 37 (63.8%) in the HAART group (p < or = 0.0001). Mean survival time for all patients was 11 +/- 16.8 months. Survival was significantly shorter in patients not receiving HAART (4.8 +/- 7.6 months) as compared with those who did (14 +/- 19.2) (p=0.01).
  
  
  CONCLUSIONS
  Patients with NHL-HIV who were able to receive treatment with HAART and were sufficiently healthy to receive optimal chemotherapy treatment showed a significantly better prognosis.
authors.affiliation: Departamento de Enfermedades infecciosas, Instituto Nacional de Cancerología, DF México. patcornejo@yahoo.com
authors.forename: Patricia
authors.initials: P
authors.lastname: Cornejo-Juárez
authors.forename: Patricia
authors.initials: P
authors.lastname: Volkow-Fernández
authors.forename: Alejandro
authors.initials: A
authors.lastname: Avilés-Salas
authors.forename: Ernesto
authors.initials: E
authors.lastname: Calderón-Flores
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002173:Cancer Care Facilities / Q000706:statistics & numerical data*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy / Q000453:epidemiology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000453:epidemiology*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000453:epidemiology*; D008297:Male; D008800:Mexico / Q000453:epidemiology; D008875:Middle Aged; D012189:Retrospective Studies; D055815:Young Adult